Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Fostair indicated for maintenance and reliever therapy

The product license for Fostair® (beclometasone and formoterol) pressurised metered dose inhaler (pMDI) has been updated with a new indication to allow use as maintenance and reliever therapy.

The Summary of Product Characteristics advises that patients can take one inhalation of the inhaler regularly twice daily for maintenance and then take up to six additional inhalations as needed in response to symptoms.

Symbicort® (budesonide and formoterol) dry power inhalers (DPI) are already licensed in this way. The license extension for Fostair® now gives clinicians and patients a choice of delivery device (pMDI or DPI).

Action: Clinicians should be aware of the license extension. Patients who prefer pMDI devices may find this product more acceptable.

Thanks to Kevin Ashworth for highlighting this information

Share 'Fostair indicated for maintenance and reliever therapy' on Email Share 'Fostair indicated for maintenance and reliever therapy' on Delicious Share 'Fostair indicated for maintenance and reliever therapy' on Digg Share 'Fostair indicated for maintenance and reliever therapy' on Facebook Share 'Fostair indicated for maintenance and reliever therapy' on Google+ Share 'Fostair indicated for maintenance and reliever therapy' on reddit Share 'Fostair indicated for maintenance and reliever therapy' on StumbleUpon Share 'Fostair indicated for maintenance and reliever therapy' on Twitter

atomic-wealth

No Comments to “Fostair indicated for maintenance and reliever therapy”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,309 spam comments.

atomic-wealth
fond-illness
summer